Affymetrix Appoints Susan Desmond-Hellmann to Board of Directors
November 22 2004 - 8:30PM
PR Newswire (US)
Affymetrix Appoints Susan Desmond-Hellmann to Board of Directors
SANTA CLARA, Calif., Nov. 22 /PRNewswire-FirstCall/ -- Today,
Affymetrix Inc. (NASDAQ:AFFX) announced that Susan
Desmond-Hellmann, M.D., President of Product Development at
Genentech Inc., has been elected to the Company's Board of
Directors. "We are very pleased to add Dr. Desmond-Hellmann to the
Company's Board," said Stephen P.A. Fodor, Ph.D., Chairman and
Chief Executive Officer, Affymetrix Inc. "Her proven track record
at Genentech has led to the successful development and launch of
many breakthrough cancer drugs -- including Herceptin, Rituxan and
Avastin -- and Affymetrix will see tremendous benefit from her
experience as we move into the clinical diagnostics area." "The
development of GeneChip(R) technology over a decade ago
fundamentally changed the way that researchers examine the genome
and has led to increased understanding of the relationship between
genes and human health," said Dr. Desmond-Hellmann. "I look forward
to working with this world-class organization as they continue to
pioneer technologies and develop tools that will improve quality of
life." In 2004, 2003 and 2001, Dr. Desmond-Hellmann was named to
FORTUNE magazine's Top 50 Most Powerful Women in Business list. She
is currently responsible for Genentech's Medical Affairs,
Regulatory Affairs, Product Development, Development Sciences and
Quality functions, as well as Business Development and Strategic
Pipeline Development. In addition to her work at Genentech, Dr.
Desmond-Hellmann is an Adjunct Associate Professor of Epidemiology
and Biostatistics at the University of California, San Francisco
(UCSF), and has also served as Assistant Professor,
Hematology-Oncology. She spent two years as visiting faculty at the
Uganda Cancer Institute studying AIDS and cancer, as well as two
years in private practice before returning to research. In 2002,
she was named to the U.S. Department of Health and Human Services
Advisory Committee on Regulatory Reform. Dr. Desmond-Hellmann was
named to the Board of Directors of the Biotechnology Industry
Organization (BIO) in 2001, where she now serves on the Board's
Executive Committee. Since 1980, she has received many honors and
awards for her work in oncology and AIDS research. Dr.
Desmond-Hellmann is board-certified in internal medicine and
medical oncology and completed her clinical training at UCSF.
Desmond-Hellmann holds bachelor and medical degrees from the
University of Nevada, Reno, as well as a master's degree in
epidemiology and biostatistics from the University of California,
Berkeley, School of Public Health. About Affymetrix: Affymetrix is
a pioneer in creating breakthrough tools that are driving the
genomic revolution. By applying the principles of semiconductor
technology to the life sciences, Affymetrix develops and
commercializes systems that enable scientists to improve quality of
life. The Company's customers include pharmaceutical,
biotechnology, agrichemical, diagnostics and consumer products
companies as well as academic, government and other non-profit
research institutes. Affymetrix offers an expanding portfolio of
integrated products and services, including its integrated GeneChip
brand platform, to address growing markets focused on understanding
the relationship between genes and human health. Additional
information on Affymetrix can be found at
http://www.affymetrix.com/. All statements in this press release
that are not historical are "forward-looking statements" within the
meaning of Section 21E of the Securities Exchange Act as amended,
including statements regarding Affymetrix' "expectations,"
"beliefs," "hopes," "intentions," "strategies" or the like. These
include statements related to the value of Dr. Susan
Desmond-Hellmann's experience and expertise to Affymetrix, which
are prospective. Such statements are subject to risks and
uncertainties that could cause actual results to differ materially
for Affymetrix from those projected, including, but not limited to
risks of the Company's ability to achieve and sustain higher levels
of revenue, higher gross margins, reduced operating expenses,
uncertainties relating to technological approaches, manufacturing,
product development, market acceptance, personnel retention,
uncertainties related to cost and pricing of Affymetrix products,
dependence on collaborative partners, uncertainties relating to
sole source suppliers, uncertainties relating to FDA and other
regulatory approvals, competition, risks relating to intellectual
property of others and the uncertainties of patent protection and
litigation. These and other risk factors are discussed in
Affymetrix' Form 10-K for the year ended December 31, 2003 and
other SEC reports, including its Quarterly Reports on Form 10-Q for
subsequent quarterly periods. Affymetrix expressly disclaims any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in Affymetrix' expectations with regard thereto
or any change in events, conditions, or circumstances on which any
such statements are based. NOTE: Affymetrix, the Affymetrix logo,
and GeneChip are registered trademarks owned or used by Affymetrix
Inc. DATASOURCE: Affymetrix, Inc. CONTACT: media, Wes Conard,
Associate Director, Public Relations, +1-408-731-5791, or
investors, Doug Farrell, Vice President, Investor Relations,
+1-408-731-5285, both of Affymetrix Inc. Web site:
http://www.affymetrix.com/
Copyright
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Oct 2023 to Oct 2024